Abstract: The present invention provides coating compositions that include an epoxy-modified fatty acid ester resin, an oxirane-functional resin different from the epoxy-modified fatty acid ester resin, a carboxyl functional polyester resin, and an alkyl acid phosphate.

Abstract: Curable compositions comprising polythioether polymers and polybasic acid-based polyepoxies, and methods of using curable compositions comprising polythioether polymers and polybasic acid-based polyepoxies are disclosed. Cured, curable compositions exhibit enhanced corrosion resistance and adhesion upon exposure to fuels.

Abstract: Polymerization processes in a bulk loop reactor are described herein. In particular, a method of contacting a flow of metallocene with a flow of propylene is provided. This method includes directing the flow of metallocene towards a junction, directing the flow of propylene towards the junction and maintaining a portion of the flow of metallocene separate from a portion of the flow propylene within a portion of the junction downstream of the flow of propylene into the junction. In another embodiment, a method of introducing a quantity of antifouling agent into a catalyst mixing system is provided. In this embodiment a portion of the antifouling agent is introduced at or downstream of a point of contact of a stream of propylene with a stream of catalyst. The antifouling agent may be a member, alone or in combination with other members, selected from Stadis 450 Conductivity Improver, Synperonic antifouling agent, and Pluronic antifouling agent.

Abstract: A cationic Group 3 or Lanthanide metal complex for coordination polymerization of olefins is disclosed. The precursor metal complex is stabilized by an anionic multidentate ancillary ligand and two monoanionic ligands. The ancillary ligand and the transition metal form a metallocycle having at least five primary atoms, counting any ?-bound cyclopentadienyl group in the metallocycle as two primary atoms. Olefin polymerization is exemplified.

Abstract: A process for polymerizing 1-butene, optionally with up to 30% by mol of ethylene, propylene or an alpha olefin of formula CH2?CHT wherein T is a C3-C10 alkyl group, in the presence of a catalyst system obtainable by contacting a metallocene compound of formula (I) Wherein M is an atom of a transition metal; X is a hydrogen atom, a halogen atoms or a hydrocarbon group; R1, R2, R5, R6, R7, R8 and R9 are hydrogen atoms or hydrocarbon groups; with the proviso that at least one of R6 or R7 is a C1-C20 alkyl group; R3 and R4 are C1-C20 alkyl groups; and an alumoxane and/or a compound capable of forming an alkyl metallocene cation

Abstract: A polymeric material having enhanced oxygen permeability and ion and water transport rates comprises units of a first monomer and a second monomer, which comprises linear poly(ethylene oxide), cyclic poly(ethylene oxide), or combinations thereof. Medical devices, such as ophthalmic devices, are made from such polymeric materials.

Abstract: A norbornene-based polymer, which is formed by addition polymerization of a composition comprising at least one norbornene derivative represented by formula (1): wherein R1, R2, R3, R4, R5, R6, R7 and R8 each independently represents a hydrogen atom or a substituent; and n represents an integer of 0 to 2.

Abstract: A process for preparing a water-soluble carboxyl group-containing polymer comprising reacting an ?,?-unsaturated carboxylic acid with a compound having at least two ethylenically unsaturated groups in an inert solvent in the presence of a radical polymerization initiator, the process for preparing a water-soluble carboxyl group-containing polymer being characterized in that the ?,?-unsaturated carboxylic acid is further added to a reaction mixture in which 20 to 70% by mol of an unreacted ?,?-unsaturated carboxylic acid remains, and the ?,?-unsaturated carboxylic acid is reacted with the compound having at least two ethylenically unsaturated groups; and a water-soluble carboxyl group-containing polymer obtainable by the above-mentioned process, wherein the reducing ratio of viscosity of a 0.2% by weight neutralized viscous liquid is less than 25%, and the equilibrium viscosity of the neutralized viscous liquid is 20000 to 50000 mPa·s.

Abstract: The present invention provides curable and cured propylene-based elastomers, optionally including a diene, and having isotactic polypropylene crystallinity, a melting point by DSC equal to or less than 110° C., and a heat of fusion of from 5 J/g to 50 J/g. The present invention also provides blend compositions comprising any of the propylene-based elastomers described herein. The present invention also provides compositions comprising any of the propylene-based elastomers described herein and 1 to 100 parts by weight of inorganic filler per 100 parts of polymer. The present invention also provides films, fibers, fabrics, molded objects, and extruded forms which include any of the inventive compositions described herein.

Abstract: The invention relates to isocyanate adducts which can be prepared by reacting at least one polyisocyanate with compounds having at least two hydrogen atoms which are reactive toward isocyanate groups and have a crystalline content of less than 10 J/g determined by differential scanning calorimetry in accordance with DIN 51 004 at 20 K/min from room temperature to 250° C. using a nitrogen flow of 3 l/h as carrier gas and an aromatics content reported as carbon atoms in aromatic rings of less than 31% by weight, based on the total weight of the isocyanate adducts.

Abstract: Provided are a catalyst for producing polycarbonate comprising a reaction product obtained by reacting (a) a catalyst carrier containing nitrogen or phosphorus with (b) a palladium compound and (c) a metal compound having a redox catalytic ability and a production process for polycarbonate, comprising a first step in which an aromatic dihydroxy compound and monovalent phenol are reacted with carbon monoxide and oxygen to produce a polycarbonate prepolymer and a second step in which the above polycarbonate prepolymer is subjected to solid state polymerization to produce polycarbonate, wherein the above catalyst is used in the first step described above.

Abstract: A process for removing metal species from a composition comprising contacting: a. an oligomer mixture stream comprising the monomers of a partially aromatic polyester polymer and at least one metal species, or b. a molten polyester polymer stream comprising partially aromatic polyester polymers and at least one metal species, with a non-catalytic porous material in the presence of hydrogen to produce a treated stream containing a reduced amount of at least one metal species. There is also provided a composition comprising a partially aromatic polyester polymer having an It.V. of at least 0.50 produced in a direct esterification melt phase process, from greater than 0 to less than 50 ppm antimony, and less than 40 ppm cobalt. There is also provided a composition comprising partially aromatic polyester polymers having an It.V. of at least 0.50 produced in an ester exchange melt phase process, from greater than zero to less than 5 ppm titanium, and less than 10 ppm manganese.

Abstract: Disclosed are peptides having SEQ ID NOs: 1 to 32 that can stimulate superoxide generation in human monocytes. Superoxide is the most important armory on the primary defense line of monocytes against invading pathogens, and the identification of new stimuli and the characterization of the regulatory mechanism of superoxide generation are of paramount importance.

Abstract: A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen.

Abstract: The present invention relates to polypeptides that inhibit the NF-?B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.

Abstract: A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X1X1PX2X3X2P(X2X2P)nX2X3(X5)0; (SEQ ID NO:23) X1X1PX2X3X4(X5)rPX2X3X3; (SEQ ID NO:24) X1X1X3(PW)uX3X2X5X2X2X5X2(X5)0; and (SEQ ID NO:25) X1X1X3X3X2P(X2X2P)nX2(X5)m; (SEQ ID NO:26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine X3 represents Arginine or Lysine; X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.

Abstract: A biologically active peptide having the amino acid sequence tyrosine-glycine-serine-arginine-serine (SEQ ID NO: 1), as well as compositions prepared from such peptide, possessing anti-cancer activity and anti-inflammatory activity, and a method for producing such a peptide and composition. The peptide is obtained by utilizing a heating, extracting and condensing system that efficiently recovers the derivatives from a raw material.

Abstract: The invention concerns a method for binding, in solution, at least a peptide composition and at least a lipophilic vector bearing an aldehyde function, the coupling comprising a step which consists in producing a hydrazone bond between the peptide compound and the lipophilic vector. The invention also concerns lipophilic vectors for use in this method, lipopeptides obtained by this method, uses of the lipopeptides for cell screening, and the applications of the invention, in particular for preparing targeting of an active principle of the peptide kind (for example hormone or neuropeptide) through physiological barriers such as cell membranes.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides having sequence similarity to trypsinogen and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention relates to a novel soluble IL-1 receptor accessory molecule (IL-1R AcM) protein which is a member of the Ig superfamily. In particular, isolated nucleic acid molecules are provided encoding the human IL-1R AcM protein. IL-1R AcM polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Screening methods are futher provided for identifying agonist and antagonists of IL-1 signal transduction. The invention further relates to methods for treating physiologic and pathologic disease conditions with IL-1R AcM antagonists.

Abstract: A recombinant bifunctional fusion protein comprises a first component which is the antigenic ectodomain of measles virus hemagglutinin protein (MeaH) genetically modified not to bind to human cells; and a second component fused thereto which is capable of binding to the surface structure of genetically variable viruses such as HCV or HIV or other therapeutic targets. The second component binds to the target and the first component is recognised by anti-measles antibodies present in the majority of the population. The protein may be used therapeutically to treat HCV or HIV infection or against other therapeutic targets.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: Experimental autoimmune encephalomyelitis (EAE) is a Th1-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). In this study it was demonstrate that CXCL13, a chemokine involved in the development of secondary lymphoid tissues, is expressed in CD11c+ myeloid cells that accumulate in EAE lesions. Blockade or deficiency of CXCL13 ameliorates clinical EAE, both during acute and relapsing stages. CXCL13 deficiency did not inhibit the priming or differentiation of autoimmune effector T-cells in the periphery, but appeared to exert its effects during the effector phase of pathogenesis. These findings indicate that reagents that antagonize or inhibit CXCL13 are useful for the treatment of neuroinflammatory diseases such as MS.

Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the compositions to treat or immunize individuals.

Abstract: The present invention relates to a novel trisazo reactive dyestuff compound of the following formula (I): wherein, R, A, B, D, and m are defined the same as in the specification. The trisazo reactive dyestuff compound of the present invention exhibits the properties of good solubility, good alkali-resistant solubility, and good wash-off, while dyeing cellulose fibers.

Abstract: The present invention provides compounds having the formula: wherein A is CH or N; B is chosen from OH, NH2, NHR, H or halogen; D is chosen from OH, NH2, NHR, H, halogen or SCH3; R is an optionally substituted alkyl, aralkyl or aryl group; and X and Y are independently selected from H, OH or halogen except that when one of X and Y is hydroxy or halogen, the other is hydrogen; and Z is OH or, when X is hydroxy, Z is selected from hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted alkyl, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof; and compounds having the formula: wherein A, X, Y, Z and R are defined for compounds of formula (I) where first shown above; E is chosen from CO2H or a corresponding salt form, CO2R, CN, CONH2, CONHR or CONR2; and G is chosen from NH2, NHCOR, NHCONHR or NHCSNHR; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug the

Abstract: Disclosed are nucleic acid molecules encoding polypeptides of the telomerase complex. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.

Abstract: The present invention relates to novel protozoal cyclic GMP dependent protein kinases and genes encoding same that have been isolated from Eimeria maxima and Plasmodium falciparum. Nucleic acid molecules having sequences that encode such proteins as well as antibodies raised against such proteins are also disclosed. These enzymes may be used in screening assays to identify potential antiprotozoal agents. As well, methods to obtain such nucleic acid molecules, proteins, antibodies and inhibitor are also provided as are therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors as well as their use to protect animals from disease caused by parasites such as Eimeria maxima and Plasmodium falciparum.

Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.

Abstract: Isolated GSTO2 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as GSTO2 allozymes. Methods for determining if a subject contains a GSTO2 sequence variant also are described.

Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogues and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogues, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).

Abstract: This invention relates to novel cyclic malonamides having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.

Abstract: The invention relates to the field of production of lactams from aminonitriles, and in particular to the production of ?-caprolactam by the vapor phase hydrolytic cyclization of 6-aminocapronitrile. A crude liquid caprolactam comprising ?-caprolactam (CL), 6-aminocapronitrile (ACN) and water obtained from a vapor phase cyclization reaction of ACN is contacted with hydrogen in the presence of a hydrogenation catalyst to convert the ACN in the crude liquid caprolactam to a product comprising hexamethylenediamine (HMD) and hexamethyleneimine (HMI). Tetrahydroazepine (THA) in the crude liquid caprolactam is converted to HMI during this hydrogenation. The HMD and HMI have lower boiling points compared to ACN and thus they are more easily separated from CL in the subsequent distillation operations. Thus a process to make CL from ACN with fewer distillation stages, and with lower pressure drop and lower base temperature, is accomplished.

Abstract: Included within the scope of the present invention are potent taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient is also included. A method for inducing cell death in selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent is included as well.

Abstract: The present invention relates to a new process for the synthesis of high purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine of formula (I) using 2,3-dichlorobenzoyl cyanide and an aminoguanidine salt as starting materials. 2,3-dichlorobenzoyl cyanide is reacted with 1-2 mol equivalent of aminoguanidine salt in 3-6 mol equivalent of methanesulfonic acid, then the obtained adduct of formula (IV) is transformed without isolation into the product with magnesium oxide.

Abstract: The present invention relates to a novel silane coupling agent represented by Formula 1 below and a method for manufacturing the same. Because the compound has urethane and pyridine functional groups, it has superior storage stability and good adhesion property to a matrix resin having hydroxy groups, and thus can be used in a variety of applications. where each of R1 and R2 is hydrogen or C1-C3 alkyl, a is an integer from 0 to 3, each of R3, R4, R5 and R6 is hydrogen, C1-C10 alkyl, halogen, trifluoroalkyl or alkoxyalkyl and n is an integer from 1 to 3.

Abstract: This invention relates to novel fluorinated dyes or colorants having high solubility and low viscosity in halogenated, especially fluorinated, solvents. The dyes or colorants of the present invention have shown to improve the performance of electrophoretic displays.

Abstract: Novel benzamide compounds of Formula (I), Formula (II) and Formula (III, salts, water soluble salts, analogs and radiolabeled counterparts thereof as sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors. A method for diagnosing a mammal for the presence of a mammalian tumor therein comprises administering to the mammal a diagnostic imaging detectable effective amount of a benzamide compound having a structure illustrated in Formula (I), Formula (II) and Formula (III) and detecting binding of the compound to a tumor in the mammal. A method for diagnostic imaging of a mammalian tissue having cell surface sigma-2 receptors comprising administering to a mammal a diagnostic imaging amount of a compound having a structure illustrated in Formula (I) Formula (II) and Formula (III) and detecting an image of a tissue having an ample cells with sigma-2 receptors.

Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4, and R5 are as defined in the specification. Compounds of the invention are active on the GABAB receptor and are useful for treating a variety of CNS disorders, including anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity-and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastro-intestinal disorders.

Abstract: Sterically hindered N-hydrocarbyloxyamines are prepared from hindered amine N-oxyl compounds by a process which uses hydrogen peroxide or a hydrogen peroxide equivalent, a catalytic amount of a peroxide decomposing transition metal salt, metal oxide, or metal-ligand complex, a hydrocarbon solvent containing no activated hydrogen atoms, and a relatively inert cosolvent. These compounds are useful as thermal and light stabilizers for a variety of organic substrates.

Abstract: The present invention relates to a piperidine compound represented by the formula [I]: wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R1 represents an optionally substituted hydoxyl group, a substituted thiol group, a substituted sulfonyl group, etc., or a group represented by the formula: R11 represents a substituted carbonyl group or a substituted sulfonyl group, R12 represents hydrogen atom or an optionally substituted alkyl group, R2 represents hydrogen atom, etc., Z represent oxygen atom or a group represented by —N(R3)—, R3 represents an optionally substituted alkyl group, etc., R4a represents an optionally substituted alkyl group, R4b represents an optionally substituted alkyl group, or a pharmaceutically acceptable salt thereof, having an excellent tachykinin receptor antagonistic action.

Abstract: The present invention relates to substantially pure piperidine derivative compounds of the formulae: wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; R3 is —COOH or —COOR4; R4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.

Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, d